---
title: "Actinium Pharmaceuticals (ATNM.US) surged nearly 17% during regular trading to $1.61"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302740107.md"
description: "Actinium Pharmaceuticals rose 16.67% to $1.61 after ATNM-400 showed pan-tumor potential with 93% inhibition in ovarian cancer at EANM."
datetime: "2026-10-22T18:09:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302740107.md)
  - [en](https://longbridge.com/en/news/302740107.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302740107.md)
generator: "portal-rs"
---

# Actinium Pharmaceuticals (ATNM.US) surged nearly 17% during regular trading to $1.61

Actinium Pharmaceuticals (ATNM.US) surged nearly **17%** during regular trading to **$1.61**.

The company presented new preclinical data for ATNM-400 at the EANM 2026 conference, demonstrating pan-tumor potential of the HER3-targeted radiopharmaceutical in lung, colorectal and ovarian cancer models. The drug showed efficacy against EGFR, KRAS and ALK driver mutations in non-small cell lung cancer, while combination therapy increased tumor growth inhibition to **72%** in colorectal cancer. In ovarian cancer, monotherapy achieved a **93%** inhibition rate even after bevacizumab failure.

Separately, the Phase 1 trial of ATNM-400 in metastatic castration-resistant prostate cancer has advanced to higher dose levels. Preliminary results from the first three patients showed no dose-limiting toxicities or serious adverse events, and HER3-targeted imaging indicated sustained tumor uptake as the study seeks to determine the recommended Phase 2 dose.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [ATNM.US](https://longbridge.com/en/quote/ATNM.US.md)

## Related News & Research

- [Actinium Advances ATNM-400 to Higher Dose in Phase 1 Prostate Cancer Trial](https://longbridge.com/en/news/302419089.md)
- [Actinium Pharmaceuticals Publishes Presentation on ATNM-400 Antitumor Activity in Ovarian Cancer Models](https://longbridge.com/en/news/302306950.md)
- [Actinium Pharmaceuticals to Present Early Phase 1 Data for ATNM-400 in Prostate Cancer at EANM](https://longbridge.com/en/news/301978571.md)
- [Actinium Pharmaceuticals CSO Kamal Adeela files initial beneficial ownership statement](https://longbridge.com/en/news/298644673.md)
- [Micron Suffers a 99.8% Snub From Its Union, Exposing AI's Human Fault Line](https://longbridge.com/en/news/303110941.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**